Literature DB >> 14706445

Targeted photodynamic therapy via receptor mediated delivery systems.

Wesley M Sharman1, Johan E van Lier, Cynthia M Allen.   

Abstract

Targeted photodynamic therapy (PDT) offers the opportunity of enhancing photodynamic efficiency by directly targeting diseased cells and tissues. While antibody-conjugates have received the most attention, cellular transformations offer numerous other potent targets to exploit during the delivery of photosensitizers (PSs) for PDT. Alterations in receptor expression, increased levels of specific cell surface membrane lipids and proteins as well as changes in the cellular microenvironment all occur in diseased cells. Along with other biochemical and physiological changes that occur during diseased and malignant cell transformation, these factors have been utilized in order to improve the efficacy of PDT. Attempts have been made to either increase the uptake of the dye by the target cells and tissues or to improve subcellular localization so as to deliver the dye to photosensitive sites within the cells. This review discusses various PS bioconjugates that utilize these factors and summarizes the results obtained to date.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706445     DOI: 10.1016/j.addr.2003.08.015

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  54 in total

1.  Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.

Authors:  Tiancheng Liu; Lisa Y Wu; Clifford E Berkman
Journal:  Cancer Lett       Date:  2010-05-08       Impact factor: 8.679

Review 2.  Photodynamic therapy for focal ablation of the prostate.

Authors:  Nimalan Arumainayagam; C M Moore; Hashim U Ahmed; M Emberton
Journal:  World J Urol       Date:  2010-05-09       Impact factor: 4.226

3.  Optimization of a nanomedicine-based silicon phthalocyanine 4 photodynamic therapy (Pc 4-PDT) strategy for targeted treatment of EGFR-overexpressing cancers.

Authors:  Alyssa M Master; Megan Livingston; Nancy L Oleinick; Anirban Sen Gupta
Journal:  Mol Pharm       Date:  2012-07-19       Impact factor: 4.939

Review 4.  Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells.

Authors:  Halina Mojzisova; Stéphanie Bonneau; Daniel Brault
Journal:  Eur Biophys J       Date:  2007-07-13       Impact factor: 1.733

Review 5.  Photodynamic therapy for prostate cancer--a review of current status and future promise.

Authors:  Caroline M Moore; Doug Pendse; Mark Emberton
Journal:  Nat Clin Pract Urol       Date:  2009-01

6.  Stability enhanced polyelectrolyte-coated gold nanorod-photosensitizer complexes for high/low power density photodynamic therapy.

Authors:  Zhenzhi Shi; Wenzhi Ren; An Gong; Xinmei Zhao; Yuehong Zou; Eric Michael Bratsolias Brown; Xiaoyuan Chen; Aiguo Wu
Journal:  Biomaterials       Date:  2014-05-20       Impact factor: 12.479

Review 7.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

8.  In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.

Authors:  Tiancheng Liu; Lisa Y Wu; Joseph K Choi; Clifford E Berkman
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

9.  Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.

Authors:  Zhiwei Hu; Benqiang Rao; Shimin Chen; Jinzhong Duanmu
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

Review 10.  Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges.

Authors:  Alyssa Master; Megan Livingston; Anirban Sen Gupta
Journal:  J Control Release       Date:  2013-03-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.